Company Performance Metrics
Vicuron Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products for the treatment of seriously ill patients. Its lead products are in Phase III clinical trials and include anidulafungin, a novel antifungal agent; and dalbavancin, a novel intravenous antibiotic
for the treatment of serious Gram-positive infections. The company�s products also include ramoplanin, which is an oral nonabsorbable form of antibiotic that selectively inhibits Gram-positive bacteria, and various types of vancomycin-resistant enterococci and Clostridia. In addition, it provides VIC-Acne, a topical antibiotic cream that is in Phase I clinical trail. Vicuron Pharmaceuticals has research collaboration agreements with Novartis Pharma AG to develop deformylase inhibitors as new antibacterial agents and to provide target-based screens; and Pfizer, Inc. to discover second and third generation oxazolidinones. The company was incorporated as Versicor, Inc. in 1995 and changed its name to Vicuron Pharmaceuticals, Inc. in 2003. Vicuron Pharmaceuticals is headquartered in King of Prussia, Pennsylvania. Vicuron Pharmaceuticals Inc. is a former subsidiary of Pfizer Inc.
